Synergy Pharmaceuticals Begins Phase IIb Trial of Plecanatide in Irritable Bowel Syndrome With Constipation (IBS-C)

[at noodls] – NEW YORK, Dec. 27, 2012 — Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that dosing has commenced in a Phase … more

View todays social media effects on SGYPU

View the latest stocks trending across Twitter. Click to view dashboard

See who Synergy is hiring next, click here to view